Obesity Connect
  • Saved

4d

Did you know?

While GLP-1 receptor agonists have established efficacy in obesity, dual agonism of both GIP and GLP-1 receptors has demonstrated superior weight loss in Phase 3 trials. The SURMOUNT-1 trial (n=2,539 adults with obesity without diabetes) found that the highest approved dose of tirzepatide achieved a mean body weight reduction of 22.5% from baseline over 72 weeks, compared to 2.4% with placebo (p<0.001) — the largest weight loss effect observed in any pharmacological obesity trial to date, approaching surgical outcomes.

NCCN Guidelines
Discussion question

As dual GIP/GLP-1 agonism achieves weight loss that approaches bariatric surgery outcomes, how is this changing your treatment algorithm for severe obesity — and how are you addressing the anticipated long-term therapy duration needed to maintain weight loss?

  • 4d
    GIP/GLP 1 agonists are more acceptable to patients over surgery. As obesity is a major cause of many many chronic medical issues and death- addressing it as a priority is Show More
  • 1w
    I am using this regularly in my practice, tirzepatide more than semaglutide when well tolerated. Cost barriers are still the most prohibitive factor, but once we get to a point Show More

Show More Comments

  • Saved

6d
Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study. - PubMed

Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42754274

Explore the GOAL trial's insights on semaglutide's role in managing antipsychotic-associated obesity in adolescents (12-18 years). Study completion rates are the primary focus.


The GOAL trial assesses semaglutide's feasibility for obesity in adolescents (12-18 years) on antipsychotics, with doses up to 2.4 mg, focusing on completion rates.

  • Saved

1w
Background Image DesktopBackground Image Mobile

A 2025 review found obesity is a chronic disease of excess dysfunctional adipose tissue and chronic inflammation linked to T2D, CVD, and metabolic syndrome. A weight-inclusive precision approach is supported by pharmacological and lifestyle intervention evidence.

Explore obesity chronic disease evidence 

  • 1w
    The disease effect a massive number of Americans and mentions the availability of highly effective medical treatment treatments
  • 1w
    This disease kills the mist Americans. We are fortunate we have numerous, efficacious medicines at our disposal.
  • Saved

1w
Clinical inertia in cardiovascular risk management: prevalence, associated factors, and impact on outcomes of the OPM study. - PubMed

Clinical inertia in cardiovascular risk management: prevalence, associated factors, and impact on outcomes of the OPM study. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42726073

Clinical inertia is prevalent in managing cardiovascular risk in primary care, leading to smaller reductions in cholesterol levels, but not affecting glycaemic parameters or triglycerides.


Clinical inertia affects over half of high-risk patients with uncontrolled hypertension, diabetes, or dyslipidaemia, leading to smaller reductions in total and LDL cholesterol.

  • Saved

1w

Did you know? Obesity is a chronic, relapsing neurobiological disease driven by dysregulation of appetite-regulating hormones and energy homeostasis. GLP-1 receptor agonism reduces caloric intake centrally and slows gastric emptying. In the STEP 1 trial, once-weekly semaglutide achieved sustained weight reductions with many patients losing more than 15% of body weight, along with meaningful improvements in cardiometabolic risk factors.

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

NCCN Guidelines

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

  • 1w
    Framing obesity as a chronic disease takes the onus of causality somewhat off the patient's shoulders. It also reinforces the need for lifelong lifestyle changes. This enhances the Show More
  • 2w
    I APPROACH OBESITY AS A CHRONIC , METABOLIC CONDITION JUST LIKE DIABETES AND HYPERTENSION AND OFFER MEDICATIONS TO COMBAT THIS DISEASE ALONG WITH LIFESTYLE MODIFICATIONS.

Show More Comments